Contraceptive transcervical fallopian tube occlusion devices and their delivery

Information

  • Patent Grant
  • 8066007
  • Patent Number
    8,066,007
  • Date Filed
    Monday, July 31, 2006
    18 years ago
  • Date Issued
    Tuesday, November 29, 2011
    12 years ago
Abstract
The invention provides intrafallopian devices and non-surgical methods for their placement to prevent conception. The efficacy of the device is enhanced by forming the structure at least in part from copper or a copper alloy. The device is anchored within the fallopian tube by imposing a secondary shape on a resilient structure, the secondary shape having a larger cross-section than the fallopian tube. The resilient structure is restrained in a straight configuration and transcervically inserted within the fallopian tube, where it is released. The resilient structure is then restrained by the walls of the fallopian tube, imposing anchoring forces as it tries to resume the secondary shape.
Description
FIELD OF THE INVENTION

The present invention relates generally to contraception, and more particularly to intrafallopian contraceptive devices and nonsurgical methods for their delivery.


Worldwide demand exists for safe, effective methods of both contraception and permanent sterilization. Although a variety of contraception and sterilization methods are available, all of the existing methods have limitations and disadvantages. Thus, the need for additional safe, low cost, reliable methods of contraception and permanent sterilization, both in developed and less developed countries, is widely recognized.


Many presently available contraception methods require significant user involvement, and user non-compliance results in quite high rates of failure. While the theoretical effectiveness of existing contraceptives, including barrier methods and hormonal therapies, is well established, overcoming user noncompliance to improve overall efficacy has proven difficult.


One form of contraception which is less susceptible to user noncompliance is the intrauterine device (IUD). IUDs have been found to have higher rates of reliability, and are effective for a longer period of time, than most other commercially available contraceptives. Unfortunately, IUDs are also associated with serious infectious complications. For this reason, the use of IUDs within the United States has decreased dramatically. Additionally, IUDs are subject to unplanned expulsion, and must be removed due to excessive pain or bleeding in a percentage of cases, further reducing the acceptance of the IUD as a contraceptive method. Interestingly, the efficacy of copper IUDs appears to be higher than that of non-metallic IUDs. The reason for this has not been fully explained.


Commercially available options for permanent sterilization include fallopian tube ligation and vasectomy. These methods are surgical, are difficult to reverse, and are not available to many people in the world. It is common knowledge that fertilization occurs in the fallopian tubes where the sperm and ovum meet. Tubal ligation avoids this by complete occlusion of the fallopian tubes.


It has previously been proposed to reversibly occlude the fallopian tubes, for example, by in vitro formation of an elastomeric plug, or otherwise anchoring a device on either side of the narrowest region of fallopian tube, called the “isthmus.” Such fallopian tube occlusion methods appear promising; however, an unacceptably high percentage of the non-surgical devices proposed to date have become dislodged during previous studies. Even where non-surgical intrafallopian devices have remained in place, they have been found to be only moderately effective at preventing conception.


For these reasons, it would be desirable to provide effective, reliable intrafallopian devices for contraception and sterilization. It would be particularly desirable to provide highly effective intrafallopian devices which did not require surgery for placement. It would be especially desirable if such devices and methods allowed easy placement of the device, but were less susceptible to being dislodged than previously proposed non-surgical intrafallopian devices.


DESCRIPTION OF THE RELATED ART

The experimental use of a stainless steel intrafallopian device is described in Transcatheter Tubal Sterilization in Rabbits, Penny L. Ross, RT 29 “Investigative Radiology”, pp. 570-573 (1994). The experimental use of an electrolytically pure copper wire as a surgical contraceptive intrafallopian device in rats was described in “Antifertility Effect of an Intrafallopian Tubal Copper Device”, D.N. Gupta, 14 Indian Journal of Experimental Biology, pp. 316-319 (May 1976).


U.K. Patent Application Pub. No. 2,211,095 describes a uterine screw plug for blocking the fallopian tube. European Patent Application Pub. No. 0,010,812 describes a device for placement in the oviducts having enlargements at either end for anchoring the device. The same device appears to be described in Netherlands Patent No. 7,810,696.


The use of tubal occlusion devices is described in “Hysteroscopic Oviduct Blocking With Formed-in-Place Silicone Rubber Plugs”, Robert A. Erb, Ph.D., et al., The Journal of Reproductive Medicine, pp. 65-68 (Aug. 1979). A formed-In-place elastomeric tubal occlusion device is described in U.S. Pat. No. 3,805,767, issued to Erb. U.S. Pat. No. 5,065,751, issued to Wolf, describes a method and apparatus for reversibly occluding a biological tube. U.S. Pat. No. 4,612,924, issued to Cimber, describes an intrauterine contraceptive device which seals the mouths of the fallopian tubes.


German Patent No. 28 03 685, issued to Brundin, describes a device for plugging a body duct with a device which swells when in contact with a body fluid.


Alternative contraceptive devices are disclosed in copending U.S. patent application Ser. No. 08/475,252, the full disclosure of which is herein incorporated by reference.


SUMMARY OF THE INVENTION

The present invention provides intrafallopian devices and methods for their placement to prevent conception. The intrafallopian devices of the present invention are transcervically delivered, resiliently anchored structures which are formed at least in part from copper to provide long term contraception, or alternatively permanent sterilization, without the need for surgical procedures or the increased bleeding, pain, and risks of infection associated with intrauterine devices (IUDs).


The use of copper in the intrafallopian device of the present invention improves its efficacy as a contraceptive method. Devices formed from plastically deformable materials, however, are less readily restrained in the fallopian tube. Apparently, the large variation in the actual shape and dimensions of fallopian tubes does not provide reliable anchoring for a pre-formed deformable intrafallopian device. The intrafallopian device of the present invention therefore comprises a resilient structure, usually a metallic coil, which includes a copper alloy, a copper plating, or copper fibers, ideally comprising an alloy including at least 75% copper. The coil material typically includes beryllium, zinc, stainless steel, platinum, a shape memory alloy such as Nitinol™, or the like. Preferably, the coil is composed of an alloy of beryllium and copper. Although the present device will generally result in occlusion, it need not completely occlude the fallopian tube to prevent the meeting of the sperm and ovum. Instead, the presence of the copper on the resilient structure is sufficient to provide effective contraception.


Conveniently, the present invention further comprises non-surgical placement of such intrafallopian devices by transcervical introduction. The resilient structure is restrainable in a straight configuration, e.g., by inserting the device within a catheter, greatly facilitating and reducing the risks of introduction. Thus, the cost and dangers associated with existing surgical contraceptive and sterilization procedures are avoided.


In a first aspect, a contraceptive intrafallopian device according to the present invention comprises a resilient structure having a proximal end and a distal end. The resilient structure comprises copper, and is biased to form at least one bend near the proximal end of the primary coil. Similarly, the resilient structure is also biased to form at least one bend near its distal end. These proximal and distal bends define an isthmus-traversing region therebetween. Preferably, the isthmus-traversing region also includes at least one bend, thereby helping to anchor the coil within the fallopian tube.


Generally, the resilient structure of the present intrafallopian device will be formed as a primary coil. To help restrain the coil within the fallopian tube, fibers are attached to some embodiments of the coil, the fibers optionally comprising a polyester material such as Rayon™, Dacron™, or the like. Alternatively, copper fibers may be used to increase the exposed copper surface area, the copper fibers generally having a diameter on the order of 0.001 inches.


The bends of the present intrafallopian device are generally formed as a secondary shape imposed on a primary coil. The primary coil is most easily formed as a straight cylindrical coil. The secondary shape will be imposed on the primary coil by bending, optionally heat treating the primary coil while bent. The individual bends may take a wide variety of forms, including sinusoidal curves, the individual loops of a continuous secondary coil, or the like. However, the secondary shape generally defines an overall width which is larger than the fallopian tube, so that the tubal wall restrains the resilient structure when it is released.


Preferably, each of the bends of the present intrafallopian device forms a loop in the primary coil when in a relaxed state. Ideally, the loops are separated by straight sections of coil. The alternating of loops with straight sections of coil forms a large diameter “flower coil,” which provides a large relaxed overall width, and also features bends at tight radius, both of which promote retention. Conveniently, the primary coil generally has a diameter less than that of the fallopian tube, and can be restrained in a straight configuration for placement within the fallopian tube, typically by inserting the primary coil within a delivery catheter.


In another aspect, a contraceptive intrafallopian device according to the present invention comprises a resilient primary coil having a primary coil diameter. The primary coil comprises copper, and forms a secondary shape when in a relaxed state. The secondary shape defines a plurality of bends and an overall width which is larger than the primary coil diameter. Thus the primary coil can be easily anchored in a fallopian tube which is smaller in diameter than the secondary shape. Preferably, the present device reacts with a force sufficient to prevent axial movement of the device within the fallopian tube when restrained in a lumen having a diameter in the range between 0.5 mm and 3 mm. The actual anchoring force will depend on the shape of the coil and the modulus of elasticity of the material used.


In yet another aspect, a intrafallopian contraceptive delivery system according to the present invention comprises an elongate body in which the resilient primary coil described above is slidably disposed. A shaft is also slidably disposed within the elongate body and is located proximally of the primary coil. The distal end of the shaft includes a coil interface surface, while the elongate body restrains the primary coil in a straight configuration.


Preferably, a bend in the isthmus-traversing region of the present intrafallopian device, together with the proximal and distal anchor bends, restrains the resilient structure within the isthmus of the fallopian tube. The distal anchor is inserted into the ampulla, distal of the isthmus, while the proximal anchor is located in the ostium, proximal of the isthmus. Unintended movement of the device is further avoided by locating the isthmus-traversing region within the isthmus to resiliently impose anchoring forces against the tubal wall.


In a still further aspect, an intrafallopian contraceptive method according to the principles of the present invention comprises restraining a resilient structure in a straight configuration and transcervically inserting the resilient structure into a fallopian tube. The resilient structure is affixed within the isthmus by releasing a bent isthmus-traversing region. The bend of the isthmus-traversing region exerts a force against the wall of the fallopian tube, anchoring the device within the isthmus. Preferably, a distal anchor on the resilient structure is released distally of the isthmus, and a proximal anchor is released proximally of the isthmus, the distal and proximal anchors generally formed from bends in the resilient structure. Optionally, an electric current is applied through the resilient structure to the fallopian tube, thereby effecting permanent sterilization.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 illustrates a first embodiment of a contraceptive intrafallopian device according to the present invention having a single distal anchor loop, a single proximal anchor loop, and an isthmus-traversing region having a single loop for anchoring the device within the fallopian tube.



FIG. 2 illustrates an alternative embodiment of a contraceptive intrafallopian device according to the present invention having a plurality of loops which may act as proximal, distal, or lumen anchors.



FIG. 3 illustrates the distal portion of a delivery catheter for placement of a contraceptive intrafallopian device according to the present invention.



FIG. 4 illustrates the contraceptive intrafallopian device of FIG. 1 partially released from the delivery catheter of FIG. 3.



FIGS. 5 and 6 illustrate a contraceptive method using an intrafallopian device according to the principles of the present invention.





DETAILED DESCRIPTION OF THE SPECIFIC EMBODIMENT

The present invention encompasses a contraceptive intrafallopian device which can alternatively be used as both a permanent and a reversible means of contraception. The present contraceptive methods and devices minimize the danger of non-use which has limited the efficacy of prior art contraceptive techniques. Moreover, the location of the present devices within the fallopian tubes provides a reduced risk of the infectious complications, increased bleeding, and pelvic pain associated with intrauterine devices (IUDs). Furthermore, the location and the novel shape of the present intrafallopian device provides significant advantages over IUDs, which have been found to be susceptible to unplanned expulsion and removal due to excessive pain and bleeding. The present invention takes advantage of the increase in effectiveness associated with copper IUDs, providing a resilient structure including copper which may be transcervically positioned without the need for surgery.


Although the present contraceptive method may be included within a group of contraceptive techniques generally referred to as fallopian tube occlusion methods, the present invention does not necessarily rely solely on blocking the fallopian tube to prevent fertilization. Instead, contraception is apparently provided by disrupting of ovum transport, the process of fertilization, and/or cleavage of the ovum. While the effect that copper has on these processes is not fully understood, it does appear that copper intrafallopian devices offer potentially significant increases in effectiveness over intrafallopian devices formed of other materials. Optionally, the present invention further encompasses devices which promote tissue growth within the tube to induce tubal occlusion, further inhibiting conception.


The present invention is anchored within the isthmus of the fallopian tube, overcoming the unintended expulsion of the device and the resulting failure of the contraceptive method. Such intrafallopian device expulsion has been the single greatest factor limiting the efficacy of easily positioned intrafallopian contraceptive techniques.


The present intrafallopian devices are generally elongate resilient structures preformed into secondary shapes. These secondary shapes will bias the resilient structure so as to provide strong forces against the lumen wall of the fallopian tube. Clearly, the secondary shape must have a larger outer diameter than the inner diameter of the fallopian tube.


Conveniently, the present resilient structures are insertable into a catheter, the catheter wall restraining the resilient structure in a straight configuration. As the resilient structure has an outer diameter when in the straight configuration which is less than the inner diameter of the fallopian tube, the catheter containing the present intrafallopian device is easily transcervically introduced. Moreover, the device is readily removed by snaring the resilient structure near the proximal end and pulling proximally on the resilient structure, thereby straightening the resilient structure and allowing it to be withdrawn without injuring the fallopian tube. Alternatively, an electrical current is applied to the device after it is at least partially releasing the fallopian tube, providing permanent sterilization.


Referring now to FIG. 1, a first embodiment of the present contraceptive intrafallopian device 10 is formed from a resilient primary coil 12. Primary coil 12 is most easily originally formed as a straight cylindrical coil or spring, preferably having an outer diameter in the range from 0.2 mm to 5 mm, and having a length in the range from 20 mm to 150 mm. Ideally, primary coil 12 has an outer diameter in the range from 0.4 DUD to 2 mm and a length in the range from 30 mm to 70 mm. The straight primary coil may then be bent into a variety of secondary shapes.


The primary coil 12 of intrafallopian device 10 includes a proximal end 14 and a distal end 16. Between these ends, three loops 20 are formed, each having an inner diameter 22. Located between loops 20 are straight sections 24, which increase the overall cross-section of the intrafallopian device to an overall width 26. Preferably, inner diameter 22 is in the range from 2 mm to 10 mm, while overall width 26 is at least 6 mm, ideally being in the range from 8 mm to 40 mm. Distal and proximal ends 14, 16 each include an atraumatic endcap 18 to prevent injury to the fallopian tube.


Preferably, primary coil 12 is formed from a beryllium copper alloy wire. Beryllium copper provides the resilience necessary to avoid expulsion of the device, and also provides the increased effectiveness of a copper contraceptive intrafallopian device. Alternatively, primary coil 12 is formed from a resilient metal, such as stainless steel, platinum, a shape memory alloy, or the like. If such materials are used, primary coil 12 is preferably plated with copper or a copper alloy or otherwise has copper attached.


To further reduce the possibility of expulsion of intrafallopian device 10, fibers are optionally carried on primary coil 12. The fibers may be short individual fibers, or may alternatively be wound into primary coil 12. Preferably, the fibers comprise copper, thereby increasing the total copper surface area. Such copper fibers are preferably bonded to primary coil 12 with solder, brazing, a polymeric adhesive, or the like. Alternatively, polyester fibers such as Dacron™, Rayon™, or the like, are bonded to the surface of primary coil 12 using a polymeric adhesive. The polyester fibers promote increased tissue growth around the coil, thus further reducing the possibility of expulsion of the device from the fallopian tube.


A secondary shape has been superimposed on the primary coil to form intrafallopian device 10, the secondary shape comprising loops 20 separated by straight sections 24. This secondary shape is herein referred to as a “flower coil.” The flower coil shape is particularly advantageous in that outer diameter 26 is substantially larger than the primary coil diameter, while the individual loops 20 have relatively small inner diameters 22 which will maintain the largest possible anchoring force against the fallopian tube. Minimizing inner diameter 22 also ensures that anchoring force is applied within the fallopian tube, despite the curvature of the fallopian tube.


Referring now to FIG. 2, an alternative embodiment of the present contraceptive intrafallopian device 30 includes additional loops to ensure anchoring of the device within the fallopian tube. Alternative embodiment 30 is formed from an elongate primary coil 32 having a proximal end 34 and a distal end (not shown). Elongate primary coil 32 has an outer diameter 36 which is smaller than the isthmus of the fallopian tube, allowing the straightened intrafallopian device to be inserted easily. Elongate primary coil 32 has been bent to form a secondary shape including a larger number of loops 38 than the embodiment of FIG. 1. Loops 38 have an outer diameter 40 which is larger than the inner diameter of the fallopian tube, preventing loops 38 from assuming their relaxed shape. Loops 38 are again separated by straight sections 42 of elongate primary coil 32, increasing the overall intrafallopian device diameter 44.


In both embodiments of the present intrafallopian device 10, 30, at least one loop adjacent to the proximal end is disposed proximally of the narrowest portion of the fallopian tube, referred to as the isthmus. Similarly, at least one loop of the intrafallopian device is disposed distally of the isthmus. These proximal and distal loops act as anchors, helping to prevent proximal or distal movement of the intrafallopian device. In the embodiment of FIG. 2, at least one loop is also disposed adjacent to the isthmus of the fallopian tube, further helping to prevent unintentional expulsion.


Alternative intrafallopian device 30 may be positioned with multiple loops acting as proximal or distal anchors, or may alternatively have all but the proximal and distal anchor loops disposed along the fallopian tube to act as anchors within the lumen of that body. Advantageously, the embodiment of FIG. 2 is therefore less sensitive to variations in total fallopian tube length.


Referring now to FIG. 3, a delivery catheter for the present intrafallopian device comprises an elongate body 52 and a shaft 54. Elongate body 52 includes a lumen .56 in which shaft 54 is disposed, shaft 54 being slidable in the axial direction. Shaft 54 includes a core 58 having a tapered distal end 60, allowing the device to navigate through tortuous bends while retaining the column strength required to advance the device. Core 58 extends proximally through elongate body 52, and is capable of transferring compressive forces through the elongate body. Core 58 is typically formed from stainless steel, a stainless alloy, or the like. Disposed over distal end 60 of core 58 is pusher cap 62. Pusher cap 62 provides a low friction, deformable end piece having a distal coil interface surface 64. Pusher Cap 62 is preferably formed of a low friction polymer such as PTFE, or the like.


Intrafallopian delivery catheter 50 receives the present intrafallopian device within the distal end of lumen 56 of elongate body 52. Lumen 56 has an inner diameter which is slightly larger than outer diameter 36 of the primary coil. The present intrafallopian device is therefore straightened to a straight configuration as it is loaded proximally into the distal end of lumen 56. Elongate body 52 is sufficiently strong to restrain the primary coil in the straight configuration, but must remain sufficiently flexible to allow maneuvering within the body lumen. Elongate body 52 is preferably formed from an inelastic, flexible material such as polyurethane, PET, or the like.


Referring now to FIG. 4, intrafallopian device 10 is released from delivery catheter 50 within the fallopian tube by holding shaft 54 while proximally withdrawing elongate body 52. Distal coil interface surface 64 engages the proximal end 14 of primary coil 12. Initially, primary coil 12 is restrained in a straight configuration by elongate body 52. As elongate body 52 is withdrawn, primary coil 12 is released. When primary coil 12 is unrestrained it forms loop 20; when released within the fallopian tube it will generally be restrained by the tubal wall in a configuration between straight and the relaxed secondary shape. Preferably, the first loop released will form a distal anchor bend 66. Subsequent loops will bias primary coil 12 against the fallopian tube, and form a proximal anchor bend, in that order.


Use of the present contraceptive intrafallopian device will be described with reference to FIGS. 5 and 6. A uterine introducer canula 70 is inserted transcervically through a uterus 72 to the region of an ostium 74. Elongate body 52 is then extended distally from canula 70 into a fallopian tube 77, preferably guided under fluoroscopy. Alternatively, a hysteroscope may be used in place of canula 70. Elongate body 52 is maneuvered using a guide wire 78 past an isthmus 80.


After elongate body 52 extends past isthmus 80, guide wire 78 is removed. An intrafallopian device according to the present invention is inserted in the proximal end of elongate body 52, the intrafallopian device being restrained in a straight configuration by the elongate body. The device is advanced distally using shaft 54, the shaft and elongate body forming delivery catheter 50 (FIG. 3). Delivery catheter 50 is axially positioned so that at least one loop of the intrafallopian device is within a target region 84 adjacent to isthmus 80. Preferably, at least one loop is distal of target region 84, and at least one loop is proximal of target region 84 to form the distal and proximal anchor bends of the implanted intrafallopian device.


Once delivery catheter 50 is properly positioned, elongate body 52 may be axially withdrawn. Shaft 54 axially restrains the intrafallopian device at the target location during withdrawal of elongate body 52, as described regarding FIG. 4. As the distal end at the primary coil is released, the distal loop forms a distal anchor bend 90. Similarly, the proximal loop forms a proximal anchor bend 92. Intermediate loops are restrained within the narrow target region 84, exerting substantial anchoring forces against the walls of the fallopian tube. As seen in FIG. 6, the loops need not assume their relaxed form to provide effective distal or proximal anchors.


The present invention further encompasses permanent sterilization by passing a current through the shaft to the intrafallopian device after elongate body 52 has been partially withdrawn, but before the intrafallopian device is fully released. Fallopian tube tissue in contact with the intrafallopian device is dessechated, and thus attached to the present intrafallopian device. This action also causes permanent tubal damage, leading to the formation of scar tissue which encapsulates the intrafallopian device and causes permanent occlusion of the tubal lumen. Clearly, the resilient member/shaft interface must be conductive to allow the present non-surgical method of permanent sterilization.


In conclusion, the present invention provides a contraceptive intrafallopian device which may be positioned without surgery. While the above is a complete description of the preferred embodiments of the invention, various alternatives, modifications, and equivalents may be used. For example, a wide variety of secondary shapes, including open loops, continuous bends, sinusoidal curves, or the like, may be imposed on the primary coil. Therefore, the above description should not be taken as limiting the scope of the invention, which is defined instead solely by the appended claims.

Claims
  • 1. A female contraceptive method comprising: delivering a first expandable anchor to a first location of a female reproductive organ, the first expandable anchor being radially restrained before being delivered, the first expandable anchor being delivered through a shaft which is transcervically introduced;delivering a second expandable anchor to a second location of a female reproductive organ, the second expandable anchor being radially restrained before being delivered, the second expandable anchor being adjacent a straight section of a contraceptive device after being delivered, wherein the straight section comprises a substantial portion of the contraceptive device; andperforming an operation with the shaft after the delivery of the first expandable anchor but before the delivery of the second expandable anchor.
  • 2. A method as in claim 1 wherein the operation comprises delivering a current through the shaft.
  • 3. A method as in claim 1 wherein the first expandable anchor expands at the first location and the second expandable anchor expands at a second location after the first expandable anchor expands.
  • 4. The method as in claim 1, wherein the first expandable anchor comprises an agent to cause tissue growth and the second expandable anchor comprises an agent to cause tissue growth.
  • 5. The method as in claim 1, wherein the first expandable anchor comprises a first resilient structure and the second expandable anchor comprises a second resilient structure.
  • 6. A device comprising: a delivery shaft configured to be transcervically introduced into a female reproductive organ;a first expandable anchor coupled to the delivery shaft;a second expandable anchor coupled to the delivery shaft, the first expandable anchor being radially restrained before being delivered by the delivery shaft and the second expandable anchor being radially restrained before being delivered by the delivery shaft, the second expandable anchor being adjacent a straight section of a contraceptive device after being delivered, wherein the straight section comprises a substantial portion of the contraceptive device after being delivered, and wherein the delivery shaft is configured to perform an operation after delivering the expandable anchor and before delivering the second expandable anchor.
  • 7. A device as in claim 6 wherein the first expandable anchor expands at a first location and the second expandable anchor expands at a second location after the first expandable anchor expands.
  • 8. A device as in claim 7 wherein the first expandable anchor and the second expandable anchor each comprise a pre-formed resilient structure which is adapted to resiliently engage a surrounding wall of a fallopian tube.
  • 9. A device as in claim 8 further comprising fibers coupled to each of the first expandable anchor and the second expandable anchor, the fibers promoting tissue growth in a fallopian tube.
  • 10. The device as in claim 6, wherein the first expandable anchor comprises an agent to cause tissue growth and the second expandable anchor comprises an agent to cause tissue growth.
  • 11. The device as in claim 6, wherein the first expandable anchor comprises a first resilient structure and the second expandable anchor comprises a second resilient structure.
  • 12. A device comprising: a delivery shaft configured to be transcervically introduced into a female reproductive organ;a first expandable anchor disposed on the delivery shaft;a second expandable anchor disposed on the delivery shaft, the first expandable anchor being radially restrained before being delivered by the delivery shaft and the second expandable anchor being radially restrained before being delivered by the delivery shaft, the second expandable anchor being adjacent a straight section of a contraceptive device after being delivered, wherein the straight section comprises a substantial portion of the contraceptive device after being delivered, and wherein the delivery shaft is configured to perform an operation after delivering the first expandable anchor and before delivering the second expandable anchor.
  • 13. A device as in claim 12 wherein the first expandable anchor expands at a first location and the second expandable anchor expands at a second location after the first expandable anchor expands.
  • 14. A device as in claim 13 wherein the first expandable anchor and the second expandable anchor each comprise a pre-formed resilient structure which is adapted to resiliently engage a surrounding wall of a fallopian tube.
  • 15. A device as in claim 14 further comprising: fibers coupled to each of the first expandable anchor and the second expandable anchor, the fiber promoting tissue growth in a fallopian tube.
  • 16. The device as in claim 12, wherein the first expandable anchor comprises an agent to cause tissue growth and the second expandable anchor comprises an agent to cause tissue growth.
  • 17. The device as in claim 12, wherein the first expandable anchor comprises a first resilient structure and the second expandable anchor comprises a second resilient structure.
  • 18. A device comprising: a delivery shaft configured to be transcervically introduced into a female reproductive organ;a first expandable element designed to prevent axial movement coupled to the delivery shaft;a second expandable element designed to prevent axial movement coupled to the delivery shaft, the first expandable element being radially restrained before being delivered by the delivery shaft and the second expandable element being radially restrained before being delivered by the delivery shaft, the second expandable element being adjacent a straight section of a contraceptive device after being delivered, wherein the straight section comprises a substantial portion of the contraceptive device after being delivered, and wherein the delivery shaft is configured to perform an operation after delivering the first expandable element and before delivering the second expandable element.
  • 19. A device as in claim 18 wherein the first expandable element expands at a first location and the second expandable element expands at a second location after the first expandable element expands.
  • 20. A device as in claim 19 wherein the first expandable element and the second expandable element each comprise a pre-formed resilient structure which is adapted to resiliently engage a surrounding wall of a fallopian tube.
  • 21. A device as in claim 20 further comprising: fibers coupled to each of the first expandable element and the second expandable element, the fiber promoting tissue growth in a fallopian tube.
  • 22. The device as in claim 18, wherein the first expandable anchor comprises an agent to cause tissue growth and the second expandable anchor comprises an agent to cause tissue growth.
  • 23. The device as in claim 18, wherein the first expandable anchor comprises a first resilient structure and the second expandable anchor comprises a second resilient structure.
  • 24. A device comprising: a longitudinally disposed member having a distal portion and a proximal portion;a first expandable anchor coupled to the longitudinally disposed member near the distal portion, the first expandable anchor being radially restrained before being delivered to a fallopian tube;a second expandable anchor coupled to the longitudinally disposed member near the proximal portion, the second expandable anchor being radially restrained before being delivered to a fallopian tube, the second expandable anchor being adjacent a straight section of a contraceptive device after being delivered, wherein the straight section comprises a substantial portion of the contraceptive device after being delivered;a delivery shaft coupled to the longitudinally disposed member, the delivery shaft being adapted to introduce the longitudinally disposed member into the fallopian tube and to detach from the longitudinally disposed member to leave the longitudinally disposed member within the fallopian tube.
  • 25. A device as in claim 24 wherein the first expandable anchor expands at a first location after being delivered and the second expandable anchor expands at a second location after being delivered and wherein the first expandable anchor expands before the second expandable anchor expands.
  • 26. A device as in claim 24 wherein the first expandable anchor and the second expandable anchor each comprise a preformed resilient structure which is adapted to resiliently engage a surrounding wall of the fallopian tube.
  • 27. A device as in claim 26 further comprising fibers coupled to the female contraceptive device.
  • 28. The device as in claim 24, wherein the first expandable anchor comprises an agent to cause tissue growth and the second expandable anchor comprises an agent to cause tissue growth.
  • 29. The device as in claim 24, wherein the first expandable anchor comprises a first resilient structure and the second expandable anchor comprises a second resilient structure.
Parent Case Info

This application is a continuation of U.S. patent application Ser. No. 10/846,047, filed May 14, 2004, which is a continuation of U.S. patent application Ser. No. 09/591,874, filed Jun. 12, 2000, now U.S. Pat. No. 6,871,650, entitled “Contraceptive Transcervical Fallopian Tube Occlusion Devices and Their Delivery”, which is a continuation of U.S. patent application Ser. No. 08/474,779, filed Jun. 7, 1995, now U.S. Pat. No. 6,176,240, entitled “Contraceptive Transcervical Fallopian Tube Occlusion Devices and Their Delivery”.

US Referenced Citations (243)
Number Name Date Kind
2102270 Hyams Dec 1937 A
2365296 Schimpf Dec 1944 A
3042030 Read Jul 1962 A
3334629 Cohn Aug 1967 A
3404682 Waldron Oct 1968 A
3405711 Bakunin Oct 1968 A
3422813 Braley et al. Jan 1969 A
3463141 Mozolf Aug 1969 A
3467090 Zollett Sep 1969 A
3561438 Canel Feb 1971 A
3563235 Zipper Feb 1971 A
3598115 Horne, Jr. Aug 1971 A
3620212 Fannon et al. Nov 1971 A
3675639 Cimber Jul 1972 A
3675642 Lord Jul 1972 A
3680542 Climber Aug 1972 A
3687129 Nuwavser Aug 1972 A
3722500 Robinson Mar 1973 A
3760806 Leeper Sep 1973 A
3763856 Blomberg Oct 1973 A
3768102 Kwan-Gett et al. Oct 1973 A
3774600 Cognat Nov 1973 A
3803308 Zipper Apr 1974 A
3805767 Erb Apr 1974 A
3840016 Lindemann Oct 1974 A
3858571 Rudolph Jan 1975 A
3858586 Lessen Jan 1975 A
3868956 Alfidi et al. Mar 1975 A
3895634 Berger et al. Jul 1975 A
3918431 Sinnreich Nov 1975 A
3926195 Bleier et al. Dec 1975 A
3938527 Rioux et al. Feb 1976 A
3973560 Emmett Aug 1976 A
3982542 Ford et al. Sep 1976 A
4003380 Wien Jan 1977 A
RE29345 Erb Aug 1977 E
4040417 Zipper Aug 1977 A
4057063 Gieles et al. Nov 1977 A
4085743 Yoon Apr 1978 A
4111196 Emmett Sep 1978 A
4135495 Borgen Jan 1979 A
4136695 Dafoe Jan 1979 A
4140126 Choudhury Feb 1979 A
4143656 Holmes Mar 1979 A
4158050 Zipper Jun 1979 A
4160446 Barrington Jul 1979 A
4181725 Voorhees et al. Jan 1980 A
4185618 Corey Jan 1980 A
4207891 Boldue Jun 1980 A
4245623 Erb Jan 1981 A
4246896 Horne, Jr. et al. Jan 1981 A
4326511 Zimerman Apr 1982 A
4353363 Sopena Quesada Oct 1982 A
4365621 Brundin Dec 1982 A
4374523 Yoon Feb 1983 A
4416660 Dafoe Nov 1983 A
4478837 Schenker Oct 1984 A
4485814 Yoon Dec 1984 A
4503569 Dotter Mar 1985 A
4509504 Brundin Apr 1985 A
4523590 Roth et al. Jun 1985 A
4537186 Verschoof et al. Aug 1985 A
4572162 Livesay et al. Feb 1986 A
4574806 McCarthy Mar 1986 A
4579110 Hamou Apr 1986 A
4595000 Hamou Jun 1986 A
4601698 Moulding, Jr. Jul 1986 A
4606336 Zeluff Aug 1986 A
4612924 Cimber Sep 1986 A
4628924 Cimber Dec 1986 A
4638803 Rand Jan 1987 A
4655771 Wallsten Apr 1987 A
4700701 Montaldi Oct 1987 A
4715365 Cimber Dec 1987 A
4717387 Inoue et al. Jan 1988 A
4724832 Strubel et al. Feb 1988 A
4727866 Livesay et al. Mar 1988 A
4731052 Seitz, Jr. Mar 1988 A
4733665 Palmaz Mar 1988 A
4788966 Yoon Dec 1988 A
4805618 Ueda et al. Feb 1989 A
4808399 Rypacek et al. Feb 1989 A
4821741 Mohajer Apr 1989 A
4824434 Seitz, Jr. Apr 1989 A
4846834 Von Recum et al. Jul 1989 A
4932421 Kaali et al. Jun 1990 A
4932422 Ragheb Jun 1990 A
4937254 Sheffield et al. Jun 1990 A
4943290 Rexroth et al. Jul 1990 A
4969458 Wiktor Nov 1990 A
4970298 Silver et al. Nov 1990 A
4983177 Wolf Jan 1991 A
4994069 Ritchart et al. Feb 1991 A
5002552 Casey Mar 1991 A
5065751 Wolf Nov 1991 A
5071407 Termin et al. Dec 1991 A
5095917 Vancaillie Mar 1992 A
5108420 Marks Apr 1992 A
5122136 Guglielmi et al. Jun 1992 A
5122137 Lennox Jun 1992 A
5133709 Prince Jul 1992 A
5147353 Everett et al. Sep 1992 A
5147370 McNamara et al. Sep 1992 A
5163958 Pinchuk Nov 1992 A
5176692 Wilk et al. Jan 1993 A
5192301 Kamiya et al. Mar 1993 A
5195964 Kletzky et al. Mar 1993 A
5197978 Hess Mar 1993 A
5207684 Nobles May 1993 A
5222964 Cooper Jun 1993 A
5226911 Chee et al. Jul 1993 A
5234437 Sepetka Aug 1993 A
5250071 Palermo Oct 1993 A
5254132 Barley et al. Oct 1993 A
5259836 Thurmond et al. Nov 1993 A
5261916 Engleson Nov 1993 A
5303719 Wilk et al. Apr 1994 A
5304194 Chee et al. Apr 1994 A
5304195 Twyford, Jr. et al. Apr 1994 A
5304228 Prince Apr 1994 A
5312415 Palermo May 1994 A
5330483 Heaven et al. Jul 1994 A
5342348 Kaplan Aug 1994 A
5346498 Greelis et al. Sep 1994 A
5350397 Palermo et al. Sep 1994 A
5354295 Guglielmi et al. Oct 1994 A
5354309 Schnepp-Pesch et al. Oct 1994 A
5356388 Sepetka et al. Oct 1994 A
5364393 Auth et al. Nov 1994 A
5366472 Hillstead Nov 1994 A
5377668 Ehmsen et al. Jan 1995 A
5382259 Phelps et al. Jan 1995 A
5382260 Dormandy et al. Jan 1995 A
5382261 Palmaz Jan 1995 A
5389089 Bauer et al. Feb 1995 A
5389100 Bacich et al. Feb 1995 A
5411549 Peters May 1995 A
5423829 Pham et al. Jun 1995 A
5423849 Engelson et al. Jun 1995 A
5433708 Nichols et al. Jul 1995 A
5443500 Sigwart Aug 1995 A
5458636 Brancato Oct 1995 A
5469867 Schmitt Nov 1995 A
5474089 Waynant Dec 1995 A
5499995 Teirstein Mar 1996 A
5507768 Lau et al. Apr 1996 A
5514176 Bosley, Jr. May 1996 A
5522822 Phelps et al. Jun 1996 A
5522836 Palermo Jun 1996 A
5534007 St. Germain et al. Jul 1996 A
5545210 Hess et al. Aug 1996 A
5549624 Mirigian et al. Aug 1996 A
5555896 Cimber Sep 1996 A
5556396 Cohen et al. Sep 1996 A
5562641 Flomenblit et al. Oct 1996 A
5562654 Smith Oct 1996 A
5569245 Guglielmi et al. Oct 1996 A
5578074 Mirigian Nov 1996 A
5582619 Ken Dec 1996 A
5601593 Freitag Feb 1997 A
5601600 Ton Feb 1997 A
5624449 Pham et al. Apr 1997 A
5624461 Mariant Apr 1997 A
5630797 Diedrich et al. May 1997 A
5634877 Salama Jun 1997 A
5656036 Palmaz Aug 1997 A
5662712 Pathak et al. Sep 1997 A
5690666 Berenstein et al. Nov 1997 A
5690842 Panchinson Nov 1997 A
5718711 Berenstein et al. Feb 1998 A
5725777 Taylor Mar 1998 A
5743905 Eder et al. Apr 1998 A
5746692 Bacich et al. May 1998 A
5746769 Ton et al. May 1998 A
5749915 Slepian May 1998 A
5755773 Evans et al. May 1998 A
5766160 Samson et al. Jun 1998 A
5766203 Imran et al. Jun 1998 A
5772669 Vrba Jun 1998 A
5795288 Cohen et al. Aug 1998 A
5807236 Bacich et al. Sep 1998 A
5843158 Lenker et al. Dec 1998 A
5876398 Mulier et al. Mar 1999 A
5885601 Sokal Mar 1999 A
5895749 Alvarez Apr 1999 A
5897551 Everett et al. Apr 1999 A
5925059 Palermo et al. Jul 1999 A
5935137 Saadat Aug 1999 A
5954715 Harrington et al. Sep 1999 A
5968052 Sullivan, III et al. Oct 1999 A
5976162 Doan Nov 1999 A
5979446 Loy Nov 1999 A
6019757 Scheldrup Feb 2000 A
6042590 Sporri et al. Mar 2000 A
6066139 Ryan et al. May 2000 A
6068626 Harrington et al. May 2000 A
6080152 Nardella et al. Jun 2000 A
6096052 Callister et al. Aug 2000 A
6143007 Mariant Nov 2000 A
6145505 Nikolchev Nov 2000 A
6156742 Mackenzie Dec 2000 A
6164280 Everett et al. Dec 2000 A
6176240 Nikolchev et al. Jan 2001 B1
6178354 Gibson Jan 2001 B1
6187027 Mariant et al. Feb 2001 B1
6270495 Palermo Aug 2001 B1
6286510 Ray et al. Sep 2001 B1
6309384 Harrington et al. Oct 2001 B1
6346102 Harrington et al. Feb 2002 B1
6357443 Loy Mar 2002 B1
6371118 Ray et al. Apr 2002 B1
6401719 Farley et al. Jun 2002 B1
6432116 Callister et al. Aug 2002 B1
6513528 Burton et al. Feb 2003 B2
6526979 Nikolchev et al. Mar 2003 B1
6550480 Feldman et al. Apr 2003 B2
6599299 Schultz Jul 2003 B2
6679266 Nikolchev et al. Jan 2004 B2
6705323 Nikolchev et al. Mar 2004 B1
6712810 Harrington et al. Mar 2004 B2
6726682 Harrington et al. Apr 2004 B2
6758831 Ryan Jul 2004 B2
6780182 Bowman et al. Aug 2004 B2
6802825 Ackerman et al. Oct 2004 B2
7073504 Callister et al. Jul 2006 B2
20010016738 Harrington et al. Aug 2001 A1
20010041900 Callister et al. Nov 2001 A1
20020013589 Callister et al. Jan 2002 A1
20020072744 Harrington et al. Jun 2002 A1
20030015203 Makower et al. Jan 2003 A1
20030029457 Callister et al. Feb 2003 A1
20030051735 Pavcnik et al. Mar 2003 A1
20030199913 Dubrul et al. Oct 2003 A1
20030220636 Bowman et al. Nov 2003 A1
20040172051 Ravikumar Sep 2004 A1
20040202694 Burbank et al. Oct 2004 A1
20040204720 Harrington et al. Oct 2004 A1
20040220585 Nikolchev Nov 2004 A1
20040255958 Harrington et al. Dec 2004 A1
20050033281 Bowman et al. Feb 2005 A1
20050045183 Callister et al. Mar 2005 A1
20050192616 Callister et al. Sep 2005 A1
20050217680 Callister et al. Oct 2005 A1
Foreign Referenced Citations (59)
Number Date Country
3252078 Jul 1979 AU
1047447 Dec 1990 CN
1073088 Jun 1993 CN
2404605 Aug 1975 DE
2525650 Dec 1976 DE
2537620 Feb 1977 DE
2635863 Feb 1977 DE
2803685 Jan 1978 DE
2803685 Aug 1979 DE
2913036 Oct 1980 DE
0010812 Oct 1979 EP
0010812 May 1980 EP
105669 Sep 1983 EP
183372 Oct 1985 EP
241971 Mar 1987 EP
421966 Sep 1990 EP
0541258 May 1993 EP
0686382 Dec 1995 EP
0739608 Oct 1996 EP
0891757 Jan 1999 EP
1460077 Dec 1976 GB
1530565 Nov 1978 GB
2010728 Jul 1979 GB
2038186 Jul 1980 GB
2150439 Jul 1985 GB
2211095 Jun 1989 GB
1-113045 May 1989 JP
5-269197 Oct 1993 JP
7810696 Apr 1980 NL
WO 8002369 Nov 1980 WO
WO 8300011 Jan 1983 WO
WO 8809648 Dec 1988 WO
WO 9306884 Apr 1993 WO
WO9406503 Mar 1994 WO
WO 9407560 Apr 1994 WO
WO 9410936 May 1994 WO
WO 9411051 May 1994 WO
WO 9424944 Nov 1994 WO
WO 9426175 Nov 1994 WO
WO 9501123 Jan 1995 WO
WO 9525490 Sep 1995 WO
WO 9622122 Jul 1996 WO
WO 9640023 Dec 1996 WO
WO 9640024 Dec 1996 WO
WO 9640024 Dec 1996 WO
WO 9708997 Mar 1997 WO
WO 9712569 Apr 1997 WO
WO 9713451 Apr 1997 WO
WO 9727893 Aug 1997 WO
WO 9746175 Dec 1997 WO
WO 9749345 Dec 1997 WO
WO 9826737 Jun 1998 WO
WO 9831308 Jul 1998 WO
WO 9855046 Dec 1998 WO
WO 9915116 Apr 1999 WO
WO 0044323 Aug 2000 WO
WO 0137760 May 2001 WO
WO 03088879 Oct 2004 WO
WO 2004098469 Nov 2004 WO
Related Publications (1)
Number Date Country
20070044808 A1 Mar 2007 US
Continuations (3)
Number Date Country
Parent 10846047 May 2004 US
Child 11497468 US
Parent 09591874 Jun 2000 US
Child 10846047 US
Parent 08474779 Jun 1995 US
Child 09591874 US